175 related articles for article (PubMed ID: 38413842)
1. Zebrafish tumour xenograft models: a prognostic approach to epithelial ovarian cancer.
Lindahl G; Fjellander S; Selvaraj K; Vildeval M; Ali Z; Almter R; Erkstam A; Rodriguez GV; Abrahamsson A; Kersley ÅR; Fahlgren A; Kjølhede P; Linder S; Dabrosin C; Jensen L
NPJ Precis Oncol; 2024 Feb; 8(1):53. PubMed ID: 38413842
[TBL] [Abstract][Full Text] [Related]
2. Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer.
Ali Z; Vildevall M; Rodriguez GV; Tandiono D; Vamvakaris I; Evangelou G; Lolas G; Syrigos KN; Villanueva A; Wick M; Omar S; Erkstam A; Schueler J; Fahlgren A; Jensen LD
J Exp Clin Cancer Res; 2022 Feb; 41(1):58. PubMed ID: 35139880
[TBL] [Abstract][Full Text] [Related]
3. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
[TBL] [Abstract][Full Text] [Related]
4. Novel Zebrafish Patient-Derived Tumor Xenograft Methodology for Evaluating Efficacy of Immune-Stimulating BCG Therapy in Urinary Bladder Cancer.
Kowald S; Huge Y; Tandiono D; Ali Z; Vazquez-Rodriguez G; Erkstam A; Fahlgren A; Sherif A; Cao Y; Jensen LD
Cells; 2023 Feb; 12(3):. PubMed ID: 36766850
[TBL] [Abstract][Full Text] [Related]
5. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
6. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial.
Li L; Zhuang Q; Cao Z; Yin R; Zhu Y; Zhu L; Xie X; Zhang Y; Li L; Wu Q; Zheng J; Zhou Q; Li X; Wu L; Feng Y; Wang C
Oncol Lett; 2018 Mar; 15(3):3646-3652. PubMed ID: 29467885
[TBL] [Abstract][Full Text] [Related]
10. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E
Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801
[TBL] [Abstract][Full Text] [Related]
11. Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer.
Huang CY; Cheng M; Lee NR; Huang HY; Lee WL; Chang WH; Wang PH
Int J Environ Res Public Health; 2020 Mar; 17(7):. PubMed ID: 32224896
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.
Dizon DS; Hensley ML; Poynor EA; Sabbatini P; Aghajanian C; Hummer A; Venkatraman E; Spriggs DR
J Clin Oncol; 2002 Mar; 20(5):1238-47. PubMed ID: 11870166
[TBL] [Abstract][Full Text] [Related]
14. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Alvarez Secord A; Bell Burdett K; Owzar K; Tritchler D; Sibley AB; Liu Y; Starr MD; Brady JC; Lankes HA; Hurwitz HI; Mannel RS; Tewari KS; O'Malley DM; Gray H; Bakkum-Gamez JN; Fujiwara K; Boente M; Deng W; Burger RA; Birrer MJ; Nixon AB
Clin Cancer Res; 2020 Mar; 26(6):1288-1296. PubMed ID: 31919136
[TBL] [Abstract][Full Text] [Related]
15. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
[TBL] [Abstract][Full Text] [Related]
16. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
17. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
18. Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer.
Ngoi NY; Syn NL; Goh RM; Goh BC; Huang RY; Soon YY; James E; Cook A; Clamp A; Tan DS
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD012007. PubMed ID: 35188221
[TBL] [Abstract][Full Text] [Related]
19. Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses.
Suvilesh KN; Nussbaum YI; Radhakrishnan V; Manjunath Y; Avella DM; Staveley-O'Carroll KF; Kimchi ET; Chaudhuri AA; Shyu CR; Li G; Pantel K; Warren WC; Mitchem JB; Kaifi JT
Mol Cancer; 2022 Mar; 21(1):73. PubMed ID: 35279152
[TBL] [Abstract][Full Text] [Related]
20. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
Lawrie TA; Rabbie R; Thoma C; Morrison J
Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]